In their article regarding the optimal revascularization threshold of fractional flow reserve (FFR) and its outcomes from their high-volume center in China, Yu et al presented their experience that an FFR of 0.80 is most appropriate for routine clinical practice. 1 These authors found that deferral of revascularization with an FFR value 0.80, including borderline lesions in a gray zone with FFR 0.76 to 0.80, is associated with significantly increased risk of coronary artery disease (CAD) events. 1 On the other hand, deferral of revascularization with FFR >0.80 resulted in excellent long-term outcomes in the presence of CAD. 1 
Definition and Determination of FFR
Accurate assessment of the severity of coronary stenoses of intermediate angiographic severity is a challenge facing interventional cardiologists every day. Fractional flow reserve, a simple but invasive technique, relies on calculating the ratio between distal and proximal arterial pressures in the coronary artery in question using specialized pressure wires. This assessment requires maximum hyperemia in the territory being tested which is achieved using intravenous (IV), or less commonly intracoronary (IC), adenosine infusion. 2 Over the last decade, the use of FFR has proven to be a reliable and reproducible tool to assess the hemodynamic significance of epicardial coronary lesions [3] [4] [5] [6] [7] and predict prognosis, especially when used to guide percutaneous coronary intervention (PCI). [8] [9] [10] [11] Subsequently, less invasive techniques have been developed to determine FFR from computed tomography (CT) angiography without a pressure wire, but the latter remains the gold standard. 10 
Meta-Analyses of FFR
A major issue of PCI is achieving complete revascularization (CR), particularly in patients with multivessel disease. Individual studies as well as meta-analyses have confirmed the superiority of CR achieved either with coronary artery bypass grafting (CABG) or with PCI in preventing CAD adverse outcomes. 12 In a meta-analysis comparing CR with incomplete revascularization for both CABG and PCI, there was a significant advantage for CR versus myocardial infarction (MI) and need for repeat coronary revascularization in both CABG and PCI groups, with CR more likely to be achieved with CABG. 12 A key issue for PCI is the identification of significant lesions that warrant intervention. In a 2017 systematic review of 51 350 patients included from 11 studies, FFR-guided PCI had an advantage over coronary angiography alone regarding both lower in-hospital and follow-up MI and major adverse cardiac event (MACE) rates. 13 A more limited 2016 study (1080 patients with PCI guided by FFR; 1058 patients with PCI guided by angiography) showed benefit, although incomplete, in that there were significantly decreased reinfarctions associated when PCI was guided by FFR, although overall MACE was not significantly different between the 2 groups.
14 Another advantage of FFR-versus angiography-guided PCI is shown in a 2016 meta-analysis of 7 studies with 49 517 patients, where FFR-guided interventions resulted in lower stent number per patient compared to angiography-guided PCI. However, the rate of reported secondary outcomes were equivalent between both strategies. 15 Despite the similar clinical end results, the smaller number of stents used with FFR would appear to have implied beneficial effects for both clinical results and overall cost. 15 In addition, the available literature confirms the safety of deferring PCI in FFR-negative lesions. 16 The FFR assessment of PCI extends beyond quantification of lesion severity to assessing the success of PCI. In a 2017 meta-analysis from 1995 to 2015 involving 105 reports including 7470 patients, there was a positive correlation between percentage of stent placement and FFR following PCI (P < .0001). 17 Higher FFR values following PCI were associated with a significantly decrease risk of needing another PCI (P < .0001) as well as decreased MACE (P ¼ .0003). 17 On the other hand, in a 2016 meta-analysis of 8 relevant studies with a total of 1337 patients, it was found that in comparison to a good FFR result, a continued low FFR after PCI was associated with worse clinical outcomes as demonstrated by increased MACE, deaths, occurrence of MI, and repeated revascularization. 18 
Coronary Computed Tomography Angiography
A calculation of FFR can also be made by coronary computed tomography angiography (CCTA) as a less invasive method than cardiac catheterization. This can be of value in deciding on whether or not cardiac catheterization is indicated. In a 2015 meta-analysis involving 5 studies, 706 patients, and a total of 1165 artery lesions, there was significant comparability for FFR determined by CCTA, with FFR measured at cardiac catheterization. 19 In this meta-analysis, there was a positive likelihood ratio for CCTA of 3.75 (95% confidence interval [CI], 2.09-6.74) on a per-vessel or per-lesion basis and pooled sensitivity for the same was 83% (95% CI, 79-87%). 19 In a 2016 meta-analysis of 7 studies involving 833 patients with 1377 vessel lesions, a similar result was obtained, showing the comparable sensitivity of FFR determined by CCTA in identifying significant coronary artery lesions. 20 It has been shown that the accuracy of CCTA varies by lesion severity, and in a 2017 review including meta-analysis of 5 studies with 536 patients including 908 coronary arteries, it was shown that there was an 82% general diagnostic accuracy for FFR values by CCTA lower than 0.63 and above 0.83, whereas there were 95% and 98% accuracy thresholds noted for CCTA values of FFR lower than 0.53 or greater than 0.93 and for lower than 0.47 or above an FFR of 0.99, respectively. 21 The CCTA has also been shown to be of value in assessing graft patency following CABG surgery. 22 With further refinements in the derivation of FFR from CCTA studies, it appears likely that CCTA will supersede invasive coronary angiography for the assessment of CABG surgery graft patency when such assessment is clinically indicated. 22 
Medications to Enhance FFR
Measurement of FFR requires maximal hyperemia with measurement of IC artery pressure proximal and distal to the stenotic lesion in question. 23 The infusion of IV adenosine is the reference method for measurement of FFR, but IC boluses frequently are used for convenience and to save time, but effectiveness needs to be better established. 24 Multiple studies have been carried out to compare the diagnostic accuracy, tolerability, and costs of IV and IC adenosine administrations in intermediate coronary lesions. However, the clinical validation of IC compared to IV adenosine has not been established, and available studies are underpowered to reach valid conclusions. In a 2018 meta-analysis, the prevalence of functionally critical CAD was not significantly different between IV adenosine administered and direct IC infusion. However, at low doses (60 mg), IC infusion had an association with higher FFR values and fewer functionally critical lesions, compared to high doses of adenosine (150 mg). 24 The IC route was associated with a higher incidence of atrioventricular blocks, whereas the IV route had a higher incidence of angina and systemic symptoms. Intracoronary adenosine may be an appropriate alternative, but establishment of standardized doses and protocols appears essential. 24 Regadenoson administered by the IV route and the IC administration of nitroprusside have both been shown to be appropriate alternatives to IV adenosine for determination of FFR, but additional validation and standardization of the clinical methodology are necessary. 23 
Acute coronary Syndrome
The use of FFR-guided revascularization in acute coronary syndrome (ACS) has a lesser prognostic value compared to stable angina. 25 The reason for this and the more emergent need for revascularization in ACS is the significantly increased incidence of MACE in spite of following a strategy of ACS revascularization determined by FFR. 26 Deferral of revascularization in the case of stable angina, as supported by FFR, does not appear to be as safe in the case of a patient with ACS due to the much higher incidence of MACE. 26 
Multivessel Coronary Artery Stenting
Current guidelines have generally recommended that in acute ST-segment elevation myocardial infarction (STEMI), PCI should generally be limited to the culprit vessel. However, there is now some contention regarding this with data as in a 2018 meta-analysis supporting performance of CR by PCI in patients with multivessel disease. 27 In this meta-analysis of 9 studies involving 3317 patients, it was shown that FFR-guided multivessel revascularization with PCI, compared to PCI of culprit lesion only, resulted in a significant reduction in MACE, need for repeat revascularization, and all-cause deaths. 27 Similar results were found in another 2018 metaanalysis involving randomized controlled trials, which concluded that multivessel stenting in patients with STEMI resulted in both decreased repeat coronary revascularizations and reduced urgent coronary revascularizations. 28 A 2019 meta-analysis determined that complete coronary revascularization guided by FFR is better than a culprit vessel-only strategy in terms of decreased MACE and decreased repeat revascularization driven by ischemia. 29 On the other hand, this 2019 meta-analysis showed essentially equal results for allcause mortality. 29 In summary, the available data confirm the safety of a multivessel FFR-guided strategy in patients with STEMI having multivessel CAD. Acute coronary syndrome was discussed above, and this term encompasses patients with STEMI, non-STEMI, and unstable angina. 30 The data discussed in this paragraph refer to STEMI only.
Left Main Coronary Artery
The safety of deferring revascularization of angiographically ambiguous left main coronary is another dilemma for the interventional cardiologist. In a 2018 review and meta-regression analysis of 908 deferred left main stenoses assessed in 12 studies, it was found that deferral of revascularization determined by both FFR and intravascular ultrasound (IVUS) resulted in an acceptable incidence of yearly MACE, the occurrence of which was 5.5% with patients with FFR and 6.4% with patients with IVUS. 31 
Coronary Microvascular Disease
Coronary microvascular disease (CMD) is frequently diagnosed in patients, with an increased incidence in women, where there is a clinical presentation of symptoms and signs suggestive of ischemic heart disease, while catheterization shows no obstructive CAD. 32 Among patients referred for coronary angiography for chest pain, 20% to 50% of them have angiographically normal coronary arteries despite documented ischemia on noninvasive testing in some of them. [33] [34] [35] This condition is not totally benign, and multiple studies have shown the association of CMD with heart failure with preserved ejection fraction (HFpEF). Therefore, a future therapeutic target for HFpEF may be microvascular dysfunction. 36 Management guidelines are not clearly defined, although there is some evidence supporting benefit from statins, angiotensin-converting enzyme inhibitors, aspirin, and antianginal agents. 32 Testing modalities include coronary reactivity testing to demonstrate decreased coronary flow reserve to adenosine, coronary artery constriction with acetylcholine as an indication of endothelial dysfunction, and adenosine stress CMR to look for coronary microvascular dysfunction. 37 Among these modalities, FFR and instant flow reserve are the most commonly used tests in the cardiac catheterization laboratory. The accuracy of these tests has been improved by the incorporation of distal coronary pressure in the calculation of the index of microcirculatory resistance obtained during maximal hyperemia with adenosine. 38, 39 Indeed, IC measurement of hyperemic microvascular resistance can be made with adenosine-induced hyperemia through employment of a Combowire (Volcano) system, and detection of increased microvascular resistance could be caused by decreased capillary and arteriolar remodeling. 40 The CMD may influence FFR to some extent, since epicardial blood flow may not be as significant as possible without the CMD, resulting in overestimation of FFR. 41 
Conclusions
The use of FFR to assist the diagnosis, prognostication, and management of CAD has made significant advances over the last decade, cementing its role in the modern cardiac catheterization laboratory. The study by Yu et al confirms the available literature in a different patient cohort not typically included in randomized studies. 1 This, and similar studies, helps generate a robust body of evidence to confirm the generalizability of FFR as a technique and to suggest future therapeutic and diagnostic uses of this novel technology.
